Ohio Doc Loses DEA License Over State Permit Slip
Published Date: 7/7/2025
Notice
Summary
Dr. Loretta Clement from Ohio lost her DEA registration because she no longer has the state permission to handle controlled substances. She didn’t ask for a hearing, so the revocation went through automatically. This means she can’t legally prescribe or manage controlled drugs anymore, effective immediately, impacting her medical practice and patients.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Clement
The DEA revoked Certificate of Registration No. FC2337500 for Loretta Clement, M.D., because she no longer has state authority to handle controlled substances in Ohio. The revocation takes effect August 6, 2025, and means she may not legally prescribe, administer, dispense, or otherwise handle controlled drugs under federal law.
Pending and New Ohio Registrations Denied
The DEA also denied any pending applications by Loretta Clement, M.D., to renew or modify her registration and denied any other pending application for additional registration in Ohio. This denial is effective August 6, 2025.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-12604 — Withdrawal of the Notice of Intent To Prepare a Supplemental Environmental Impact Statement (SEIS) for the Columbia River System Operations
The U.S. Army Corps of Engineers and Bureau of Reclamation have decided not to move forward with extra environmental studies for the Columbia River System. This means no new delays or extra costs for communities and businesses relying on the river’s operations. Everyone can expect things to keep running as planned without any surprise changes.
Next: 2025-12624 — Sunshine Act Meetings
The Legal Services Corporation is holding its summer meetings July 14-16, 2025, in Detroit, and most sessions will be open for the public to watch live or in person. Some parts might close for sensitive topics like budget plans, investigations, or legal updates. These meetings affect board members, committees, and anyone interested in how legal aid is managed, with no new costs announced.